OMITTED INFORMATION IS THE SUBJECT OF A REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
Exhibit 99.3
OMITTED INFORMATION IS THE SUBJECT OF A REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
November 13, 2007
Æterna Zentaris GmbH
D-60314 Frankfurt/Main
Germany
Attn: Xxxxxxxxx Xxxxx
Re: First Amendment to License and Cooperation Agreement for Perifosine
Dear Xx. Xxxxx,
Æterna Zentaris GmbH (formerly Zentaris AG) and AOI Pharma, Inc., a wholly-owned subsidiary of Keryx Biopharmaceuticals, Inc. are parties to a License and Cooperation Agreement for Perifosine dated September 18, 2002 (the “Agreement”). The parties wish to amend the Agreement as follows:
Section 4.2(i) of the Agreement is deleted in its entirety and replaced with the following:
“Upon the earlier to occur of: (i) completion of the first Phase II study for Perifosine conducted by AOI, its Affiliates or sublicensees, or (ii) December 31, 2007.
[**** ******* ********(1)].
Please indicate your acceptance of this First Amendment by signing below and returning one fully-executed copy to me.
Sincerely yours,
/s/ I. Xxxxx Xxxxxxxxx |
|
I. Xxxxx Xxxxxxxxx
President
AGREED & ACCEPTED
Æterna Zentaris GmbH
By: |
/s/ Xxxxxxx Xxxxx |
|
By: |
/s/ Xxxxxxxx Xxxxxx |
|
|
|
|
|
Title: |
Managing Director |
|
Title: |
Managing Director |
|
|
|
|
|
Date: |
November 29, 2007 |
|
Date: |
November 29, 2007 |
(1) Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.